- Theravance Biopharma, Inc. TBPH has agreed to sell all of its units in Theravance Respiratory Company, LLC, representing 85% economic interest in the sales-based royalty rights on worldwide net sales of GSK plc’s GSK TRELEGY ELLIPTA to Royalty Pharma RPRX for over $1.5 billion.
- The transaction is intended to provide near-, mid-and long-term value to Theravance with an upfront cash payment of ~$1.1 billion, up to $250 million in additional milestone payments, and outer year royalties to the Company providing an opportunity to receive an estimated NPV of ~$200 million.
- In 2021, Trelegy generated sales of $1.68 billion, an increase of 57% at constant exchange rates versus the prior year.
- Royalty Pharma is also acquiring 15% Innoviva INVA equity interests in Theravance Respiratory Company, LLC, for ~$282 million and a potential $50 million contingent sales-based milestone payment.
- Royalty Pharma will invest up to $40 million to advance the development of ampreloxetine in Multiple System Atrophy (MSA) in exchange for unsecured low single-digit royalties.
- Royalty Pharma expects to fund this transaction with existing cash on the balance sheet and to maintain the significant financial capacity to deploy capital in additional value-creating opportunities.
- Royalty Pharma held cash and cash equivalents of $1.79 billion as of March 31, 2022.
- Price Action: TBPH shares are trading higher by 28.16% at $11.06, INVA +10.67% at $15.45, and GSK higher by 0.20% at $41 during the post-market session on Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
